---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-26-000004"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:15:26.310516+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Xeris expects record 2025 revenue of $292M, up 44% YoY; beats guidance

## Summary
- Preliminary full-year 2025 total revenue of $292M, exceeding $285-290M guidance range, reflecting 44% YoY growth.
- Q4 Recorlev net revenue $45M; full-year Recorlev net revenue $139M.
- Gvoke revenue grew >13% YoY; Keveyis patient base expanded vs. year-end 2024.
- Positive Adjusted EBITDA delivered in each quarter of 2025.
- Full 2025 results and 2026 outlook to be released March 2, 2026.

## SEC filing metadata
- accession: 0001867096-26-000004
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000004/0001867096-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000004/xers-20260108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-26-000004
- JSON: https://secwatch.observer/filing/0001867096-26-000004.json
- Plain text: https://secwatch.observer/filing/0001867096-26-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.